146 related articles for article (PubMed ID: 37804113)
21. Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain.
Hancock TJ; Hickman P; Kazerooni N; Kennedy M; Kania SA; Dennis M; Szafranski N; Gerhold R; Su C; Masi T; Smith S; Sparer TE
J Virol; 2022 Apr; 96(8):e0025022. PubMed ID: 35352999
[TBL] [Abstract][Full Text] [Related]
22. Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.
Hu Y; Liu K; Han P; Xu Z; Zheng A; Pan X; Jia Y; Su C; Tang L; Wu L; Bai B; Zhao X; Tian D; Chen Z; Qi J; Wang Q; Gao GF
EMBO J; 2023 Feb; 42(4):e111737. PubMed ID: 36519268
[TBL] [Abstract][Full Text] [Related]
23. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope.
Liu Z; Xu W; Chen Z; Fu W; Zhan W; Gao Y; Zhou J; Zhou Y; Wu J; Wang Q; Zhang X; Hao A; Wu W; Zhang Q; Li Y; Fan K; Chen R; Jiang Q; Mayer CT; Schoofs T; Xie Y; Jiang S; Wen Y; Yuan Z; Wang K; Lu L; Sun L; Wang Q
Protein Cell; 2022 Sep; 13(9):655-675. PubMed ID: 34554412
[TBL] [Abstract][Full Text] [Related]
24. Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus.
Lee J; Zepeda SK; Park YJ; Taylor AL; Quispe J; Stewart C; Leaf EM; Treichel C; Corti D; King NP; Starr TN; Veesler D
Cell Host Microbe; 2023 Dec; 31(12):1961-1973.e11. PubMed ID: 37989312
[TBL] [Abstract][Full Text] [Related]
25. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
Ge XY; Li JL; Yang XL; Chmura AA; Zhu G; Epstein JH; Mazet JK; Hu B; Zhang W; Peng C; Zhang YJ; Luo CM; Tan B; Wang N; Zhu Y; Crameri G; Zhang SY; Wang LF; Daszak P; Shi ZL
Nature; 2013 Nov; 503(7477):535-8. PubMed ID: 24172901
[TBL] [Abstract][Full Text] [Related]
26. Biophysical evolution of the receptor-binding domains of SARS-CoVs.
Upadhyay V; Panja S; Lucas A; Patrick C; Mallela KMG
Biophys J; 2023 Dec; 122(23):4489-4502. PubMed ID: 37897042
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and Genomic Characterization of Two Novel SARS-Related Coronaviruses in Horseshoe Bats from Guangdong, China.
Li L; Zhang L; Zhou J; He X; Yu Y; Liu P; Huang W; Xiang Z; Chen J
mBio; 2022 Jun; 13(3):e0046322. PubMed ID: 35467426
[TBL] [Abstract][Full Text] [Related]
28. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
29. Comparative genetic analyses of Korean bat coronaviruses with SARS-CoV and the newly emerged SARS-CoV-2.
Na EJ; Lee SY; Kim HJ; Oem JK
J Vet Sci; 2021 Jan; 22(1):e12. PubMed ID: 33522164
[TBL] [Abstract][Full Text] [Related]
30. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
31. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
32. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
[TBL] [Abstract][Full Text] [Related]
33. Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017.
Jia Y; Niu S; Hu Y; Chai Y; Zheng A; Su C; Wu L; Han P; Han P; Lu D; Liu Z; Yan X; Tian D; Chen Z; Qi J; Tian WX; Wang Q; Gao GF
Cell Rep; 2022 Dec; 41(11):111831. PubMed ID: 36493785
[TBL] [Abstract][Full Text] [Related]
34. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
35. Structural basis of SARS-CoV-2 and its variants binding to intermediate horseshoe bat ACE2.
Tang L; Zhang D; Han P; Kang X; Zheng A; Xu Z; Zhao X; Wang VY; Qi J; Wang Q; Liu K; Gao GF
Int J Biol Sci; 2022; 18(12):4658-4668. PubMed ID: 35874946
[TBL] [Abstract][Full Text] [Related]
36. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
37. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
38. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
39. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Lan J; Ge J; Yu J; Shan S; Zhou H; Fan S; Zhang Q; Shi X; Wang Q; Zhang L; Wang X
Nature; 2020 May; 581(7807):215-220. PubMed ID: 32225176
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
Baig AM; Khaleeq A; Syeda H
J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
